Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity are Linked to Clinical Responses to 5-Azacytidine

The DNA methyltransferase inhibitors (DNMTi) 5-azacytidine (AZA) and 5-aza-2-deoxycytidine have been approved for the treatment of different types of hematological malignancies. However, only about 50% of patients respond to treatment. Therefore, a more comprehensive understanding of the molecular c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res
Autors principals: Ohtani, Hitoshi, Ørskov, Andreas D., Helbo, Alexandra S., Gillberg, Linn, Liu, Minmin, Zhou, Wanding, Ungerstedt, Johanna, Hellström-Lindberg, Eva, Sun, Weili, Liang, Gangning, Jones, Peter A., Grønbæk, Kirsten
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7507765/
https://ncbi.nlm.nih.gov/pubmed/32245794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-1696
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars